story of the week
Nintedanib or Placebo Added to Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Muscle-Invasive Bladder Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial
Lancet Oncol 2022 Apr 11;[EPub Ahead of Print], SA Hussain, JF Lester, R Jackson, M Gornall, M Qureshi, A Elliott, SJ Crabb, RA Huddart, N Vasudev, AJ Birtle, J Worlding, ND James, O Parikh, M Vilarino-Varela, R Alonzi, MD Linch, IB Riaz, JWF Catto, T Powles, RJ JonesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.